Cargando…

Soluble Syndecan-1 Levels Are Associated with Survival in Platinum-Treated Bladder Cancer Patients

Cisplatin-containing chemotherapy represents the first-line treatment for patients with locally advanced or metastatic muscle-invasive bladder cancer. Recently, novel therapies have become available for cisplatin-ineligible or -resistant patients. Therefore, prediction of cisplatin response is requi...

Descripción completa

Detalles Bibliográficos
Autores principales: Olah, Csilla, Tschirdewahn, Stephan, Hoffmann, Michèle J., Krafft, Ulrich, Hadaschik, Boris, Nyirady, Peter, Szendröi, Attila, Módos, Orsolya, Csizmarik, Anita, Kovalszky, Ilona, Reis, Henning, Szarvas, Tibor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7690724/
https://www.ncbi.nlm.nih.gov/pubmed/33114033
http://dx.doi.org/10.3390/diagnostics10110864
_version_ 1783614133890973696
author Olah, Csilla
Tschirdewahn, Stephan
Hoffmann, Michèle J.
Krafft, Ulrich
Hadaschik, Boris
Nyirady, Peter
Szendröi, Attila
Módos, Orsolya
Csizmarik, Anita
Kovalszky, Ilona
Reis, Henning
Szarvas, Tibor
author_facet Olah, Csilla
Tschirdewahn, Stephan
Hoffmann, Michèle J.
Krafft, Ulrich
Hadaschik, Boris
Nyirady, Peter
Szendröi, Attila
Módos, Orsolya
Csizmarik, Anita
Kovalszky, Ilona
Reis, Henning
Szarvas, Tibor
author_sort Olah, Csilla
collection PubMed
description Cisplatin-containing chemotherapy represents the first-line treatment for patients with locally advanced or metastatic muscle-invasive bladder cancer. Recently, novel therapies have become available for cisplatin-ineligible or -resistant patients. Therefore, prediction of cisplatin response is required to optimize therapy decisions. Syndecan-1 (SDC1) tissue expression and serum concentration may be associated with cisplatin resistance. Thus, pre-treatment serum levels of SDC1 and its expression in chemo-naïve tissues were assessed in 121 muscle-invasive bladder cancer patients who underwent postoperative platinum-based chemotherapy. SDC1 concentrations were evaluated by ELISA in 52 baseline and 90 follow-up serum samples and tissue expressions were analyzed by immunohistochemistry in an independent cohort of 69 formalin-fixed paraffin-embedded tumor samples. Pre-treatment SDC1 serum levels were significantly higher in lymph node metastatic (p = 0.009) and female patients (p = 0.026). SDC1 tissue expression did not correlate with clinicopathological parameters. High pre-treatment SDC1 serum level and the presence of distant metastasis were independent risk factors for overall survival (Hazard ratio (HR): 1.439, 95% Confidence interval (CI): 1.003–2.065, p = 0.048; HR: 2.269, 95%CI: 1.053–4.887, p = 0.036). Our results demonstrate an independent association between high baseline serum SDC1 concentration and poor survival in platinum-treated patients. Analyzing baseline serum SDC1 levels may help to predict platinum-containing chemotherapy and could help to optimize therapeutic decision-making.
format Online
Article
Text
id pubmed-7690724
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-76907242020-11-27 Soluble Syndecan-1 Levels Are Associated with Survival in Platinum-Treated Bladder Cancer Patients Olah, Csilla Tschirdewahn, Stephan Hoffmann, Michèle J. Krafft, Ulrich Hadaschik, Boris Nyirady, Peter Szendröi, Attila Módos, Orsolya Csizmarik, Anita Kovalszky, Ilona Reis, Henning Szarvas, Tibor Diagnostics (Basel) Article Cisplatin-containing chemotherapy represents the first-line treatment for patients with locally advanced or metastatic muscle-invasive bladder cancer. Recently, novel therapies have become available for cisplatin-ineligible or -resistant patients. Therefore, prediction of cisplatin response is required to optimize therapy decisions. Syndecan-1 (SDC1) tissue expression and serum concentration may be associated with cisplatin resistance. Thus, pre-treatment serum levels of SDC1 and its expression in chemo-naïve tissues were assessed in 121 muscle-invasive bladder cancer patients who underwent postoperative platinum-based chemotherapy. SDC1 concentrations were evaluated by ELISA in 52 baseline and 90 follow-up serum samples and tissue expressions were analyzed by immunohistochemistry in an independent cohort of 69 formalin-fixed paraffin-embedded tumor samples. Pre-treatment SDC1 serum levels were significantly higher in lymph node metastatic (p = 0.009) and female patients (p = 0.026). SDC1 tissue expression did not correlate with clinicopathological parameters. High pre-treatment SDC1 serum level and the presence of distant metastasis were independent risk factors for overall survival (Hazard ratio (HR): 1.439, 95% Confidence interval (CI): 1.003–2.065, p = 0.048; HR: 2.269, 95%CI: 1.053–4.887, p = 0.036). Our results demonstrate an independent association between high baseline serum SDC1 concentration and poor survival in platinum-treated patients. Analyzing baseline serum SDC1 levels may help to predict platinum-containing chemotherapy and could help to optimize therapeutic decision-making. MDPI 2020-10-23 /pmc/articles/PMC7690724/ /pubmed/33114033 http://dx.doi.org/10.3390/diagnostics10110864 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Olah, Csilla
Tschirdewahn, Stephan
Hoffmann, Michèle J.
Krafft, Ulrich
Hadaschik, Boris
Nyirady, Peter
Szendröi, Attila
Módos, Orsolya
Csizmarik, Anita
Kovalszky, Ilona
Reis, Henning
Szarvas, Tibor
Soluble Syndecan-1 Levels Are Associated with Survival in Platinum-Treated Bladder Cancer Patients
title Soluble Syndecan-1 Levels Are Associated with Survival in Platinum-Treated Bladder Cancer Patients
title_full Soluble Syndecan-1 Levels Are Associated with Survival in Platinum-Treated Bladder Cancer Patients
title_fullStr Soluble Syndecan-1 Levels Are Associated with Survival in Platinum-Treated Bladder Cancer Patients
title_full_unstemmed Soluble Syndecan-1 Levels Are Associated with Survival in Platinum-Treated Bladder Cancer Patients
title_short Soluble Syndecan-1 Levels Are Associated with Survival in Platinum-Treated Bladder Cancer Patients
title_sort soluble syndecan-1 levels are associated with survival in platinum-treated bladder cancer patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7690724/
https://www.ncbi.nlm.nih.gov/pubmed/33114033
http://dx.doi.org/10.3390/diagnostics10110864
work_keys_str_mv AT olahcsilla solublesyndecan1levelsareassociatedwithsurvivalinplatinumtreatedbladdercancerpatients
AT tschirdewahnstephan solublesyndecan1levelsareassociatedwithsurvivalinplatinumtreatedbladdercancerpatients
AT hoffmannmichelej solublesyndecan1levelsareassociatedwithsurvivalinplatinumtreatedbladdercancerpatients
AT krafftulrich solublesyndecan1levelsareassociatedwithsurvivalinplatinumtreatedbladdercancerpatients
AT hadaschikboris solublesyndecan1levelsareassociatedwithsurvivalinplatinumtreatedbladdercancerpatients
AT nyiradypeter solublesyndecan1levelsareassociatedwithsurvivalinplatinumtreatedbladdercancerpatients
AT szendroiattila solublesyndecan1levelsareassociatedwithsurvivalinplatinumtreatedbladdercancerpatients
AT modosorsolya solublesyndecan1levelsareassociatedwithsurvivalinplatinumtreatedbladdercancerpatients
AT csizmarikanita solublesyndecan1levelsareassociatedwithsurvivalinplatinumtreatedbladdercancerpatients
AT kovalszkyilona solublesyndecan1levelsareassociatedwithsurvivalinplatinumtreatedbladdercancerpatients
AT reishenning solublesyndecan1levelsareassociatedwithsurvivalinplatinumtreatedbladdercancerpatients
AT szarvastibor solublesyndecan1levelsareassociatedwithsurvivalinplatinumtreatedbladdercancerpatients